312 related articles for article (PubMed ID: 26273932)
1. Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study.
Kolomeyevskaya NV; Szender JB; Zirpoli G; Minlikeeva A; Friel G; Cannioto RA; Brightwell RM; Grzankowski KS; Moysich KB
Int J Gynecol Cancer; 2015 Nov; 25(9):1587-92. PubMed ID: 26273932
[TBL] [Abstract][Full Text] [Related]
2. Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study.
Bešević J; Gunter MJ; Fortner RT; Tsilidis KK; Weiderpass E; Onland-Moret NC; Dossus L; Tjønneland A; Hansen L; Overvad K; Mesrine S; Baglietto L; Clavel-Chapelon F; Kaaks R; Aleksandrova K; Boeing H; Trichopoulou A; Lagiou P; Bamia C; Masala G; Agnoli C; Tumino R; Ricceri F; Panico S; Bueno-de-Mesquita HB; Peeters PH; Jareid M; Quirós JR; Duell EJ; Sánchez MJ; Larrañaga N; Chirlaque MD; Barricarte A; Dias JA; Sonestedt E; Idahl A; Lundin E; Wareham NJ; Khaw KT; Travis RC; Rinaldi S; Romieu I; Riboli E; Merritt MA
Br J Cancer; 2015 Dec; 113(11):1622-31. PubMed ID: 26554655
[TBL] [Abstract][Full Text] [Related]
3. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube.
Sehouli J; Olschewski J; Schotters V; Fotopoulou C; Pietzner K
Ann Oncol; 2013 Dec; 24(12):3024-8. PubMed ID: 24130264
[TBL] [Abstract][Full Text] [Related]
5. The influence of reproductive and hormonal factors on ovarian cancer survival.
Nagle CM; Bain CJ; Green AC; Webb PM
Int J Gynecol Cancer; 2008; 18(3):407-13. PubMed ID: 17645507
[TBL] [Abstract][Full Text] [Related]
6. Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status.
Stasenko M; Plegue M; Sciallis AP; McLean K
Int J Gynecol Cancer; 2015 Feb; 25(2):222-8. PubMed ID: 25500503
[TBL] [Abstract][Full Text] [Related]
7. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
Tseng JH; Cowan RA; Afonso AM; Zhou Q; Iasonos A; Ali N; Thompson E; Sonoda Y; O'Cearbhaill RE; Chi DS; Abu-Rustum NR; Long Roche K
Gynecol Oncol; 2018 Nov; 151(2):287-293. PubMed ID: 30185381
[TBL] [Abstract][Full Text] [Related]
8. Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes.
Rottmann M; Burges A; Mahner S; Anthuber C; Beck T; Grab D; Schnelzer A; Kiechle M; Mayr D; Pölcher M; Schubert-Fritschle G; Engel J
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1833-1844. PubMed ID: 28447160
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer.
Berntsson J; Lundgren S; Nodin B; Uhlén M; Gaber A; Jirström K
J Ovarian Res; 2014 Feb; 7():26. PubMed ID: 24568264
[TBL] [Abstract][Full Text] [Related]
10. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
[TBL] [Abstract][Full Text] [Related]
11. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
[TBL] [Abstract][Full Text] [Related]
12. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.
Wahner Hendrickson AE; Hawthorne KM; Goode EL; Kalli KR; Goergen KM; Bakkum-Gamez JN; Cliby WA; Keeney GL; Visscher DW; Tarabishy Y; Oberg AL; Hartmann LC; Maurer MJ
Gynecol Oncol; 2015 Apr; 137(1):77-85. PubMed ID: 25620544
[TBL] [Abstract][Full Text] [Related]
13. Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women.
McGuire V; Hartge P; Liao LM; Sinha R; Bernstein L; Canchola AJ; Anderson GL; Stefanick ML; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1059-63. PubMed ID: 27197274
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
16. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness.
Poole EM; Merritt MA; Jordan SJ; Yang HP; Hankinson SE; Park Y; Rosner B; Webb PM; Cramer DW; Wentzensen N; Terry KL; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):429-37. PubMed ID: 23307531
[TBL] [Abstract][Full Text] [Related]
17. Impact of beta blockers on epithelial ovarian cancer survival.
Diaz ES; Karlan BY; Li AJ
Gynecol Oncol; 2012 Nov; 127(2):375-8. PubMed ID: 22819786
[TBL] [Abstract][Full Text] [Related]
18. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Martin JY; Urban RR; Liao JB; Goff BA
J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
[TBL] [Abstract][Full Text] [Related]
20. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
